益气宣痹汤治疗新冠肺炎后肺纤维化倾向可行性探讨

Feasibility of Yiqi Xuanbi Decoction in the Treatment of Post-Covid19 Pulmonary Fibrosis

随着新型冠状病毒肺炎符合出院标准的患者逐渐增多,新冠肺炎出院后肺间质纤维化倾向的治疗应该引起重视,查阅文献,并分析新冠肺炎后肺纤维化倾向的临床特征及中医分型,发现恢复期患者病机为虚实夹杂,肺气不宣,其虚以肺脾气虚或气阴两虚为主,其实以痰瘀阻络为主。益气宣痹汤具有益气宣痹、活血通络作用,为临床治疗肺间质纤维化的经验方,建议对新冠肺炎后肺纤维化倾向患者给予治疗。

Patients who meet the requirements of hospital discharge are constantly increasing,whereas the post-Covid 19 pulmonary fibrosis tends to be emphasized.This paper analyzes the clinical characteristics of post-Covid 19 pulmonary fibrosis and TCM syndrome-typing based on the literature review.It finds out that the patients in the recovery period were deficient of lung-spleen qi or deficient of both qi and Yin,which is characterized by phlegm stasis blocking collaterals.Yiqi Xuanbi Decoction,as an empirical prescription for the treatment of pulmonary fibrosis,can benefit qi and disperse bi,promote blood circulation and remove obstruction in collaterals.Therefore,it is recommended to apply this prescription to the treatment of post-Covid 19 pulmonary fibrosis.